{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:38:34Z","timestamp":1785883114095,"version":"3.56.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>B-cell acute lymphoblastic leukemia (BCP-ALL) is characterized by an abnormal proliferation of immature cells in bone marrow. Leukemic blasts at diagnosis exhibit a so-called leukemia associated immunophenotype (LAIP), which is further used for determination of measurable residual disease (MRD) levels at particular time points during the therapy. Nevertheless, in some patients LAIP proves insufficient for discrimination of blasts from their normal counterparts, therefore, search for novel, aberrant markers is essential. A crucial requirement for these antigens is their expression variability throughout the entire treatment monitoring period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The aim of the study was to assess the expression level of four markers: CD66c, CD304, CD72 and CD86 on leukemic cells at diagnosis and at day 15 and 33 of treatment to compare stability of their expression. We also correlated the results obtained with the most common genetic aberrations identified at the diagnosis of BCP-ALL, such as: hyper- hypodiploidy, <jats:italic>BCR::ABL1<\/jats:italic>, <jats:italic>KMT2A::AFF1<\/jats:italic>, <jats:italic>ETV6::RUNX1<\/jats:italic>, <jats:italic>TCF3-rearangement<\/jats:italic>, <jats:italic>TCF3::PBX1<\/jats:italic>, <jats:italic>TCF3::HLF<\/jats:italic>, <jats:italic>KMT2A<\/jats:italic> and <jats:italic>IKZF1<\/jats:italic> mutations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In more than 90% of patients, CD86 overexpression on blast cells was proven at day 15 of treatment and in almost 93% during the entire remission-inducting therapy (day 33). Similarly high positivity rate on leukemic blasts was found for CD72 antigen, which at day 15 was positive in 82% of patients and dropped to 43% at day 33 of treatment. We also found a correlation between the presence of hyperdiploidy and <jats:italic>ETV6::RUNX1<\/jats:italic> and changes in the expression of particular markers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The obtained results demonstrate that CD86 and CD72 can be successfully used as additional markers for MRD assessment in BCP-ALL.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1641088","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T04:13:37Z","timestamp":1756268017000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Expression of aberrant markers in monitoring of measurable residual disease in B-cell precursor acute lymphoblastic leukemia patients during remission-inducing therapy phase"],"prefix":"10.3389","volume":"15","author":[{"given":"\u0141.","family":"S\u0142ota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141.","family":"S\u0119dek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lejman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Perkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bulsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"M\u0142ynarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kowalczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Szczepa\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","article-title":"Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): A randomised controlled trial","volume":"14","author":"Vora","year":"2013","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21031054","article-title":"Minimal residual disease detection in acute lymphoblastic leukemia","volume":"21","author":"Kruse","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21833","article-title":"Applications of flow cytometric immunophenotyping in the diagnosis and posttreatment monitoring of B and T lymphoblastic leukemia\/lymphoma","volume":"96","author":"DiGiuseppe","year":"2019","journal-title":"Cytom Part B - Clin Cytom"},{"key":"B4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/cyto.b.21239","article-title":"Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry","volume":"90","author":"Wood","year":"2016","journal-title":"Cytom Part B - Clin Cytom"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","article-title":"Minimal residual disease diagnostics in acute lymphoblastic leukemia: Need for sensitive, fast, and standardized technologies","volume":"125","author":"Van Dongen","year":"2015","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12795","article-title":"Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia","volume":"40","author":"Tsitsikov","year":"2018","journal-title":"Int J Lab Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children\u2019s Oncology Group study","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8934","article-title":"Risk\u00a0of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow","volume":"27","author":"Basso","year":"2009","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07410.x","article-title":"Predictive value of flow cytometric minimal residual disease analysis in childhood acute lymphoblastic leukaemia at the end of remission induction therapy - Results from a single UK centre","volume":"144","author":"Motwani","year":"2009","journal-title":"Br J Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and Malignant leukocytes","volume":"26","author":"Van Dongen","year":"2012","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.312","article-title":"Immunophenotyping of acute leukemia and lymphoproliferative disorders: A consensus proposal of the European LeukemiaNet Work Package 10","volume":"25","author":"B\u00e9n\u00e9","year":"2011","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2009.07.010","article-title":"Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia","volume":"23","author":"Campana","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.7.2115","article-title":"Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia","volume":"97","author":"Chen","year":"2001","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20440","article-title":"Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: Potential usefulness in minimal residualdisease detection","volume":"76","author":"DiGiuseppe","year":"2009","journal-title":"Cytom Part B - Clin Cytom"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP02RPVOKTNWEC","article-title":"Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: Utility in detection of minimal residual disease by flow cytometry","volume":"132","author":"Muzzafar","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21486","article-title":"Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000\u2013000","volume":"94","author":"Tembhare","year":"2018","journal-title":"Cytom Part B - Clin Cytom"},{"key":"B17","doi-asserted-by":"publisher","first-page":"112429","DOI":"10.1016\/j.jim.2018.03.005","article-title":"Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia","volume":"475","author":"S\u0119dek","year":"201","journal-title":"J Immunol Methods"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-324004","article-title":"New markers for minimal residual disease detection in acute lymphoblastic leukemia","volume":"117","author":"Coustan-Smith","year":"2011","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2016.09.003","article-title":"Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies","volume":"14","author":"Ruella","year":"2016","journal-title":"Comput Struct Biotechnol J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0023-x","article-title":"CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment","volume":"7","author":"Mejstr\u00edkov\u00e1","year":"2017","journal-title":"Blood Cancer J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2018.1504680","article-title":"Flow cytometry for minimal residual disease testing in acute leukemia: opportunities and challenges","volume":"18","author":"Gaipa","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"key":"B22","unstructured":"Euroflow Consortium. EuroFlow Standard Operating Procedure (SOP) for Sample preparation and staining Version 1.4\n          \n          \n          2019"},{"key":"B23","first-page":"1","volume-title":"EuroFlow Standard Operating Procedure (SOP) for Instrument Setup and Compensation Version 1.2.1 (29 October 2019)","author":"Kalina","year":"2019"},{"key":"B24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5114\/ceji.2022.114530","article-title":"Expression of CD73 on leukemic blasts increases during follow-up \u2013 a promising candidate marker for minimal residual disease detection in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"47","author":"S\u0142ota","year":"2022","journal-title":"Cent Eur J Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.268","article-title":"Standardized MRD quantification in European all trials: Proceedings of the second international symposium on MRD assessment in Kiel, Germany, 18\u201320 September 2008","volume":"24","author":"Bruggemann","year":"2010","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0000000000000319","article-title":"The role of multiparametric flow cytometry in the detection of minimal residual disease in acute leukaemia","volume":"47","author":"Lee","year":"2015","journal-title":"Pathol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s12288-017-0845-5","article-title":"Evaluating new markers for minimal residual disease analysis by flow cytometry in precursor B lymphoblastic leukemia","volume":"34","author":"Jain","year":"2018","journal-title":"Indian J Hematol Blood Transfus"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13456","article-title":"Expression of CD304\/neuropilin-1 in adult b-cell lymphoblastic leukemia\/lymphoma and its utility for the measurable residual disease assessment","volume":"43","author":"Chatterjee","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.24790","article-title":"CD72 is a pan-tumor antigen associated to pediatric acute leukemia","volume":"103","author":"Buldini","year":"2023","journal-title":"Cytom Part A"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-553X.2010.01254.x","article-title":"CD66c expression in B-cell acute lymphoblastic leukemia: Strength and weakness","volume":"33","author":"Guillaume","year":"2011","journal-title":"Int J Lab Hematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402504","article-title":"Antigen expression patterns reflecting genotype of acute leukemia","volume":"16","author":"Hru\u0161\u00e1k","year":"2002","journal-title":"Leukemia"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5838","article-title":"Evaluation of diagnostic efficacy of NRP-1\/CD304 in hematological diseases","volume":"12","author":"Liu","year":"2023","journal-title":"Cancer Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1641088\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T04:13:39Z","timestamp":1756268019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1641088\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":33,"alternative-id":["10.3389\/fonc.2025.1641088"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1641088","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"article-number":"1641088"}}